Boston, MA -- (SBWIRE) -- 07/06/2012 -- Asthma is an established and growing market dominated by key brands. However, competition is growing and generic threats are increasing, such that the market will become more fragmented. A number of pipeline products, notably once-daily ICS/LABA combinations, are expected to address unmet needs and have high clinical and commercial potential.
- Access Datamonitor's independent clinical and commercial assessment of marketed brands and key pipeline agents for asthma.
- Understand what it takes to differentiate a product in asthma treatment and how the pipeline threatens current market leaders.
- Assess how pipeline products compare to each other and how they will compete with established therapies.
- Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
View Full Report Details and Table of Contents
Advair (GlaxoSmithKline) was the first ICS/LABA combination to launch but is expected to come under threat from generics and increasing competition, but with Phase III trials complete, its follow-on Relovair is on track to become the first once-daily ICS/LABA, which, if achieved, would ensure that the company maintains its market dominance.
Several biologics have advanced in the pipeline. Genentech's lebrikizumab is currently in large Phase III trials looking at exacerbations and AstraZeneca's tralokinumab and benralizumab are both in Phase II. Biologics could address unmet needs for subsets of uncontrolled patients, but key opinion leaders maintain skepticism over their viability.
Despite patent expiries for key ICS/LABA combinations, generics have not yet entered any of the seven major markets. Datamonitor believes that in the next couple of years they will launch as branded generics. Lower price discounts together with patients' hesitation to switch devices will help the brands resist generic erosion
Reasons to Get this Report
- How do marketed treatments of asthma compare to one another and where will pipeline agents fit in?
- How is GlaxoSmithKline protecting its market position in the face of increasing competition and looming generic entry?
- How can companies position their products at launch in order to compete in this well established market?
- How is asthma treatment expected to change as novel therapies move through the pipeline?
About Fast Market Researc
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Asthma - Pipeline Review, H2 2011
- Asthma - Pipeline Review, H1 2012
- Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- ACT Biotech, Inc. - Product Pipeline Review - H2 2011
- Pancreatic Cancer - Pipeline Review, Q2 2011
- Product Profiles: Non-Small Cell Lung Cancer
- ACT Biotech, Inc. - Product Pipeline Review - Q1 2011
- Neuralgia - Pipeline Review, Q2 2011
- Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries
- Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules